Northfield Labs Heads Permanently South

Jon C. Ogg
24/7 Wall St.



Northfield Labs (NFLD) just faced what may the knockout blow for the company. The company has been working for years now on studies for PolyHeme, its blood substitution product. This product has been touted in the past as the Holy Grail for on the scene treatment of blood loss in trauma and injury cases, yet the hopes never matched up with the results.

The company’s stock is trading down 40% pre-market after releasing that its Phase III studies failed to meet endpoints and failed to show any statistically significance. A prior result before this latest release even showed some progress that was interpreted as worse than the observation group. It just looks like the fake blood product from this company is not going to come to fruition.



Continue article at 247WallSt.com

______________________